What is the studied dose of Bacopa Monnieri?

300–600 mg daily of a standardized extract (commonly ~50% bacosides). A studied dose is what research used, not a recommended dose.

What are the side effects of Bacopa Monnieri?

GI upset, especially on an empty stomach Occasional fatigue reported

Who should avoid Bacopa Monnieri?

Pregnant or breastfeeding without clinician guidance On thyroid medication without review

Nootropic

Bacopa Monnieri

A traditional herb standardized for compounds called bacosides. It is studied mainly for memory and learning over sustained daily use, not for same-day effects.

Grade BSignal State Core candidateUpdated September 17, 2026Written and fact-checked in-house against The Evidence Standard. Not a clinical review.

Photo by Vikash Kumar meena on Pexels

Please note

Educational content, not medical advice. Doses below are ranges used in research, not recommendations. Talk to a qualified clinician before starting any supplement, especially if you take medication, are pregnant, or manage a health condition.

Evidence grade: Evidence: Grade B
Studied dose range: 300–600 mg daily of a standardized extract (commonly ~50% bacosides).
Time to effect: Typically studied over 8–12 weeks of daily use.
Best form: Standardized extract stating bacoside percentage.

The short answer

Bacopa Monnieri (Nootropic) is studied for memory support and learning over weeks. In our conservative reading of the published human research, the evidence is Grade B (moderate). 300–600 mg daily of a standardized extract (commonly ~50% bacosides). Typically studied over 8–12 weeks of daily use. A studied dose is what trials used, not a recommended dose.

Full profile

Also known as	Brahmi, Bacopa
Best for	Memory support · Learning over weeks · Daily cognitive routine
Evidence grade	Grade B · Moderate: several human trials, some mixed results
Studied dose range	300–600 mg daily of a standardized extract (commonly ~50% bacosides).
Time to effect	Typically studied over 8–12 weeks of daily use.
Best form	Standardized extract stating bacoside percentage.

Evidence, honestly graded

Multiple human trials over 8–12 weeks, from several independent research groups, report memory and learning improvements, with benefits that are cumulative rather than acute. That is the basis for B. Held at B on 2026-09-14 but now under monitoring: the most recent adequately sized trial at 300 mg (Lopresti & Smith 2025; 12 weeks; adults aged 40–70 with memory or attention complaints) found no difference from placebo on verbal learning, attention or working memory, and more adverse reactions, mostly digestive complaints and headache. A 2026 network meta-analysis (Tiemtad et al., 29 RCTs) placed the clearest working-memory gains at 600 mg/day or more, above Health Canada's 300 mg/day figure for standardized extract, though its pooled effect sizes are large enough to suggest small-study inflation. Another adequately powered null result at 300 mg would move the grade to C.

See the full grading rubric (study type, replication, population match, and dose adequacy) in The Evidence Standard.

What the benefits research does and doesn't support, in depth: Bacopa Monnieri Benefits: What Weeks of Daily Use Actually Do.

541 natural health products with an active licence in Health Canada's LNHPD list Bacopa Monnieri as a medicinal ingredient.

That makes Bacopa Monnieri a recognized, licensable medicinal ingredient in Canada, regulated by Health Canada's Natural and Non-prescription Health Products Directorate, which issues each licensed natural health product a Natural Product Number (NPN). Search the LNHPD to verify.

Source: Health Canada Licensed Natural Health Products Database, snapshot 2026-09-28. A count of products with an active licence, not an endorsement of any health claim. This describes the ingredient's regulatory standing in Canada, not Signal State Core, which is a pre-launch concept and is not a licensed natural health product.

Side effects

GI upset, especially on an empty stomach
Occasional fatigue reported

Who should avoid it or check first

Pregnant or breastfeeding without clinician guidance
On thyroid medication without review

Interactions

May interact with thyroid and sedative medications; discuss with a clinician

Stacks well with

Use caution stacking with

Additional sedating herbs without guidance

What to look for on a label

Look for the bacoside standardization percentage.
Take with food to reduce GI upset.

References

Calabrese C, Gregory WL, Leo M, et al. (2008). Journal of Alternative and Complementary Medicine, 14(6):707–713Randomized, double-blind, placebo-controlled, healthy adults 65+, 12 weeksStudied dose: 300 mg daily (≈50% bacosides)Improved delayed word recall and attention/inhibition (Stroop) versus placebo.
Morgan A, Stevens J (2010). Journal of Alternative and Complementary Medicine, 16(7):753–759Randomized, double-blind, placebo-controlled, adults 40–65, 12 weeksStudied dose: 300 mg daily standardized extractImproved verbal learning and delayed recall on the AVLT versus placebo.
Lopresti AL, Smith SJ (2025). Clinical Drug Investigation, 45(12)Randomized, double-blind, placebo-controlled, n=101 randomized (87 analysed), adults aged 40–70 with self-reported memory and attention problems, 12 weeksStudied dose: 300 mg dailyNo between-group differences in verbal learning, attention or working memory; a greater reduction in self-reported stress reactivity; more adverse reactions than placebo.
Tiemtad P, Ingkaninan K, Temkitthawon P, et al. (2026). Phytomedicine, 153Systematic review and network meta-analysis, 29 RCTs, n=2,107Bacopa at 600 mg/day or more ranked best for working memory; 300–600 mg/day outperformed ginkgo for delayed memory; no differences in attention or processing speed.

Grades and studied doses are our conservative reading of the human research, shown for education. They are not product claims, and a studied dose is not a recommended dose.

Revision history

Every change to this ingredient's evidence status, dated and explained. The full cross-library log lives at Evidence Updates.

2026-09-17Citation review
Checked whether the trigger for moving this grade to C had fired: it has not. No second adequately powered null trial at 300 mg has appeared since the 2025 one this profile already cites. Added a disclosure to that citation: the trial was run by a contract research organisation whose managing director is the first author, and its competing-interests statement refers to a funder it does not name. B holds, still under monitoring.
2026-09-14Citation review
Held at B and placed under monitoring. A 2025 twelve-week trial at 300 mg/day found no difference from placebo on verbal learning, attention or working memory, and a 2026 network meta-analysis placed the clearest working-memory gains at 600 mg/day or more.
2026-07-04New profile
Initial profile published at Grade B: multiple 8–12 week human trials report memory and learning gains, with a characteristically cumulative (not acute) time course.

See how Bacopa Monnieri compares on grade, dose, and goal in the Evidence Explorer.

Less noise. More signal.

Get the Clean Focus Stack Guide

Join the waitlist for early access to Signal State Core and we'll send the guide, along with the ingredient research behind it. No spam, just signal.

Free guide on signupEarly access at launch